The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

LILRB1  -  leukocyte immunoglobulin-like receptor,...

Homo sapiens

Synonyms: CD85, CD85 antigen-like family member J, CD85J, CD85j, ILT-2, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of LILRB1


High impact information on LILRB1


Biological context of LILRB1


Anatomical context of LILRB1


Associations of LILRB1 with chemical compounds

  • In order to identify other molecules to which CD85j might interact with in a phosphotyrosine-dependent manner, a cDNA B-cell library was screened in a three-hybrid system in yeast using the CD85j cytoplasmic tail as bait in the presence of the Src-kinase c-fyn420, 531Y-F, 176R-Q mutant [14].
  • Mutational analyses and phospho-peptide mapping suggested that the SH2 domain of Csk may preferentially bind to ITIM Y562 of CD85j; yet, mutation to phenylalanine of Y533, Y614, and Y644 also significantly reduced Csk recruitment by CD85j [14].
  • Accordingly, the mutated HLA-G transfectants were less effective in the inhibition of NK killing and RBL/LIR-1 induced serotonin release [15].
  • Mutating these cysteine residues resulted in a dramatic decrease in LIR-1 Ig binding [15].

Physical interactions of LILRB1

  • ILT2 generally bound with a 2- to 3-fold higher affinity than ILT4 to the same MHCI [13].
  • These results suggest that subtle structural differences between LILRB family members cause the distinct binding specificities to various forms of HLA-G and other MHCIs, which may in turn regulate immune suppression [16].
  • HLA-F tetramer binding could be conferred on non-binding cells by transfection with the inhibitory receptors ILT2 and ILT4 [17].
  • Both biochemical and functional analyses revealed tyrosines 644 (SIYATL) and 614 (VTYAQL) as the SHP-1 docking sites required for ILT2 inhibitory function [18].

Regulatory relationships of LILRB1

  • CD85j (leukocyte Ig-like receptor-1/Ig-like transcript 2) inhibits human osteoclast-associated receptor-mediated activation of human dendritic cells [19].
  • The formation of these complexes on the cell surface might represent a novel mechanism developed specifically by the HLA-G protein aimed to control the efficiency of the CD85J/LIR-1-mediated inhibition [20].
  • A significantly increased proportion of CD8 CTL still expressed LIR1/ILT2, a receptor with broad HLA-class I specificity [21].

Other interactions of LILRB1

  • We have used surface plasmon resonance to analyze the interaction of soluble forms of ILT4 and ILT2 with several MHCIs [13].
  • LILRB2 exhibits an overlapping but distinct MHCI recognition mode compared with LILRB1 and dominantly recognizes the hydrophobic site of the HLA-G alpha3 domain [16].
  • Several members of the immunoglobulin-like transcript (ILT), also called leukocyte immunoglobulin-like receptor (LIR), family of transmembrane proteins have been identified as receptors for class I HLA molecules and transduce inhibitory signals to leukocytes upon binding of these ligands [12].
  • The 3' untranslated region of the gene for LIR-6 contains a 37-base pair repeat not present in the LIR-1 or LIR-5 genes [22].
  • These findings demonstrated that LILRB1 is highly polymorphic and is associated with susceptibility to RA in HLA-DRB1 SE negative subjects, possibly by insufficient inhibitory signaling in leukocytes [1].

Analytical, diagnostic and therapeutic context of LILRB1


  1. Extensive polymorphisms of LILRB1 (ILT2, LIR1) and their association with HLA-DRB1 shared epitope negative rheumatoid arthritis. Kuroki, K., Tsuchiya, N., Shiroishi, M., Rasubala, L., Yamashita, Y., Matsuta, K., Fukazawa, T., Kusaoi, M., Murakami, Y., Takiguchi, M., Juji, T., Hashimoto, H., Kohda, D., Maenaka, K., Tokunaga, K. Hum. Mol. Genet. (2005) [Pubmed]
  2. Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2. Urosevic, M., Kamarashev, J., Burg, G., Dummer, R. Blood (2004) [Pubmed]
  3. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling. Nikolova, M., Musette, P., Bagot, M., Boumsell, L., Bensussan, A. Blood (2002) [Pubmed]
  4. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. Lefebvre, S., Antoine, M., Uzan, S., McMaster, M., Dausset, J., Carosella, E.D., Paul, P. J. Pathol. (2002) [Pubmed]
  5. CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Poirel, L., Naas, T., Le Thomas, I., Karim, A., Bingen, E., Nordmann, P. Antimicrob. Agents Chemother. (2001) [Pubmed]
  6. Expression of the CD85j (leukocyte Ig-like receptor 1, Ig-like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathies. Schleinitz, N., Cognet, C., Guia, S., Laugier-Anfossi, F., Baratin, M., Pouget, J., Pelissier, J.F., Harle, J.R., Vivier, E., Figarella-Branger, D. Arthritis Rheum. (2008) [Pubmed]
  7. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Cosman, D., Fanger, N., Borges, L., Kubin, M., Chin, W., Peterson, L., Hsu, M.L. Immunity (1997) [Pubmed]
  8. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Willcox, B.E., Thomas, L.M., Bjorkman, P.J. Nat. Immunol. (2003) [Pubmed]
  9. Entropically driven MHC class I recognition by human inhibitory receptor leukocyte Ig-like receptor B1 (LILRB1/ILT2/CD85j). Shiroishi, M., Kuroki, K., Tsumoto, K., Yokota, A., Sasaki, T., Amano, K., Shimojima, T., Shirakihara, Y., Rasubala, L., van der Merwe, P.A., Kumagai, I., Kohda, D., Maenaka, K. J. Mol. Biol. (2006) [Pubmed]
  10. The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. Fanger, N.A., Cosman, D., Peterson, L., Braddy, S.C., Maliszewski, C.R., Borges, L. Eur. J. Immunol. (1998) [Pubmed]
  11. Expression, purification, and refolding of the myeloid inhibitory receptor leukocyte immunoglobulin-like receptor-5 for structural and ligand identification studies. Garner, L.I., Salim, M., Mohammed, F., Willcox, B.E. Protein Expr. Purif. (2006) [Pubmed]
  12. Decidual macrophages are potentially susceptible to inhibition by class Ia and class Ib HLA molecules. Petroff, M.G., Sedlmayr, P., Azzola, D., Hunt, J.S. J. Reprod. Immunol. (2002) [Pubmed]
  13. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Shiroishi, M., Tsumoto, K., Amano, K., Shirakihara, Y., Colonna, M., Braud, V.M., Allan, D.S., Makadzange, A., Rowland-Jones, S., Willcox, B., Jones, E.Y., van der Merwe, P.A., Kumagai, I., Maenaka, K. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  14. Recruitment of C-terminal Src kinase by the leukocyte inhibitory receptor CD85j. Sayós, J., Martínez-Barriocanal, A., Kitzig, F., Bellón, T., López-Botet, M. Biochem. Biophys. Res. Commun. (2004) [Pubmed]
  15. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. Gonen-Gross, T., Achdout, H., Gazit, R., Hanna, J., Mizrahi, S., Markel, G., Goldman-Wohl, D., Yagel, S., Horejsí, V., Levy, O., Baniyash, M., Mandelboim, O. J. Immunol. (2003) [Pubmed]
  16. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Shiroishi, M., Kuroki, K., Rasubala, L., Tsumoto, K., Kumagai, I., Kurimoto, E., Kato, K., Kohda, D., Maenaka, K. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  17. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Lepin, E.J., Bastin, J.M., Allan, D.S., Roncador, G., Braud, V.M., Mason, D.Y., van der Merwe, P.A., McMichael, A.J., Bell, J.I., Powis, S.H., O'Callaghan, C.A. Eur. J. Immunol. (2000) [Pubmed]
  18. Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor. Bellón, T., Kitzig, F., Sayós, J., López-Botet, M. J. Immunol. (2002) [Pubmed]
  19. CD85j (leukocyte Ig-like receptor-1/Ig-like transcript 2) inhibits human osteoclast-associated receptor-mediated activation of human dendritic cells. Tenca, C., Merlo, A., Merck, E., Bates, E.E., Saverino, D., Simone, R., Zarcone, D., Trinchieri, G., Grossi, C.E., Ciccone, E. J. Immunol. (2005) [Pubmed]
  20. The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules. Gonen-Gross, T., Achdout, H., Arnon, T.I., Gazit, R., Stern, N., Horejsí, V., Goldman-Wohl, D., Yagel, S., Mandelboim, O. J. Immunol. (2005) [Pubmed]
  21. Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. Costa, P., Rusconi, S., Mavilio, D., Fogli, M., Murdaca, G., Pende, D., Mingari, M.C., Galli, M., Moretta, L., De Maria, A. AIDS (2001) [Pubmed]
  22. Genomic organization of the human leukocyte immunoglobulin-like receptors within the leukocyte receptor complex on chromosome 19q13.4. Liu, W.R., Kim, J., Nwankwo, C., Ashworth, L.K., Arm, J.P. Immunogenetics (2000) [Pubmed]
  23. LIR-1 expression on lymphocytes, and cytomegalovirus disease in lung-transplant recipients. Berg, L., Riise, G.C., Cosman, D., Bergström, T., Olofsson, S., Kärre, K., Carbone, E. Lancet (2003) [Pubmed]
  24. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. Saverino, D., Fabbi, M., Ghiotto, F., Merlo, A., Bruno, S., Zarcone, D., Tenca, C., Tiso, M., Santoro, G., Anastasi, G., Cosman, D., Grossi, C.E., Ciccone, E. J. Immunol. (2000) [Pubmed]
WikiGenes - Universities